Конверсия неоперабельной стадии рака легкого в операбельную у EGFR-позитивных пациентов на фоне лечения гефитинибом: два клинических случая

1. Loriot Y, Soria JC, Le Chevalier T. Expanding role of chemotherapy in lung cancer. Ann Oncol 2006; 17 (suppl. 10): x101–7.
2. Chang CH, Chen KY, Young-Xu Y et al. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 2008; 62: 242–52.
3. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58: 95–103.
4. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442–9.
5. Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745–53.
6. Okamoto T, Maruyama R, Shoji F et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005; 47: 85–91.
7. Govindan R, Behnken D, Read W, McLeod H. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 2003; 14: 1330–1.
8. Takamochi K, Suzuki K, Sugimura H et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007; 58: 149–55.
9. Kappers I, Klomp HM, Burgers JA et al. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008; 26: 4205–7.
10. Mok T, Wu YL, Thongprasert S et al. Phase III, randomised, openlabel, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008; 19 (suppl. 8): viii1.
11. Sirera R, Catot S, Gonzalez-Larriba GL et al. Customizing erlotinib in metastatic non-small sell lung cancer (NSCLC) patients (P) harboring EGFR mutations. Ann Oncol 2008; 19 (suppl. 8): viii90.
12. Altorki N, Heymach J, Guarino M et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I–II non-small cell lung cancer (NSCLC): a proof-ofconcept study. Ann Oncol 2008; 19 (suppl. 8): viii89.
13. Tsuboi M, Kato H, Nagai K et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005; 16: 1123–8.
14. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
15. Lee KH, Han SW, Hwang PG et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-smallcell lung cancer. Jpn J Clin Oncol 2006; 36: 344–50.

Е.В.Левченко, В.М.Моисеенко, Д.Е.Мацко, А.Г.Ивлева, А.О.Иванцов, С.М.Яргниан, В.В.Анисимов, И.И.Семионов, Е.Н.Имянитов

Институт онкологии им. Н.Н.Петрова, Санкт-Петербург